The FDA has approved Inrebic for the treatment of adult patients with certain types of myelofibrosis, a rare bone marrow disorder.
Inrebic, a once-daily oral capsule, is the second treatment approved in the U.S. for myelofibrosis. The drug is manufactured by Impact Biomedicines, a subsidiary of Celgene.
The drug, a kinase inhibitor, targets treatment-naive myelofibrosis, a bone marrow disorder that disrupts the normal production of blood cells.
The approval is the first new treatment for the disease in nearly a decade.
It also comes as a win for drug giant Bristol-Myers Squibb, which is finalizing its merger with Celgene.